Shell-and-core dosage form approaching zero-order drug release
View Patent ↗Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
1. A method for administering to a subject a water soluble drug that is preferentially absorbed in the upper gastrointestinal tract comprising,
orally administering a controlled-release oral drug dosage form, wherein the dosage form comprises:
(a) a core comprising a first solid polymeric matrix with said drug dispersed therein, and
(b) a shell substantially completely encasing said core, said shell comprising a second solid polymeric matrix that swells upon imbibition of water to a size large enough to promote retention in the stomach while the stomach is in a fed mode, and said shell having a drug:polymer weight ratio that is less than that of said core, said shell having a thickness that is at least about 0.5% of the longest linear dimension of said dosage form, said second polymeric matrix being of a material and thickness relative to said core such that when said dosage form is immersed in gastric fluid, said drug is released from said dosage form into said gastric fluid at a controlled rate limited at least in part by diffusion of said drug through said shell to an extent that at least about 40% of said drug remains unreleased one hour after such immersion has begun and substantially all of said drug is released within about twenty-four hours after such immersion has begun, said shell remaining intact during substantially the entire period of drug release, wherein the drug has a beneficial biological effect in the treatment of various diseases.
2. The method of claim 1 , wherein said shell thickness is from about 1% to about 60% of the longest linear dimension of said dosage form.
3. The method of claim 1 , wherein the drug:polymer weight ratio of said shell is equal to or less than about 0.5 times the drug:polymer weight ratio of said core.
4. The method of claim 1 , wherein said shell contains substantially none of said drug.
5. The method of claim 1 , wherein said oral drug dosage form is a tablet having a total weight of from about 50 mg to about 5000 mg.
6. The method of claim 1 , wherein said first and second polymeric matrices are formed of polymers independently selected from the group consisting of poly(ethylene oxide), poly(vinyl alcohol), cellulose, alkyl-substituted cellulose, hydroxyalkyl-substituted cellulose, crosslinked polyacrylic acids, and xanthan gum.
7. The method of claim 1 , wherein said first and second polymeric matrices are formed of polymers independently selected from the group consisting of poly(ethylene oxide), hydroxypropylmethyl cellulose, and hydroxyethyl cellulose.
8. The method of claim 1 , wherein said first and second polymeric matrices are both poly(ethylene oxide).
9. The method of claim 8 , wherein said poly(ethylene oxide) has a molecular weight of from about 2,000,000 to about 10,000,000.
10. The method of claim 8 , wherein said poly(ethylene oxide) of said first polymeric matrix has a higher molecular weight than said poly(ethylene oxide) of said second polymeric matrix.
11. The method of claim 8 , wherein said poly(ethylene oxide) of said first polymeric matrix has a lower molecular weight than said poly(ethylene oxide) of said second polymeric matrix.
12. The method of claim 10 , wherein the molecular weight ratio of said poly(ethylene oxide) of said first polymeric matrix to said poly(ethylene oxide) of said second polymeric matrix is from about 1.15:1 to about 2.5:1.
13. The method of claim 1 , wherein the amount of said drug in said core is from about 1% to about 98% by weight.
14. The method of claim 1 , wherein said second polymeric matrix is of a material and volume relative to said core that at least about 40% of said drug remains unreleased two hours after such immersion has begun.
15. The method of claim 1 , wherein said second polymeric matrix is of a material and volume relative to said core that at least about 60% of said drug remains unreleased two hours after such immersion has begun.
16. The method of claim 1 , wherein said drug has a solubility in water of greater than one part by weight of said drug in 25 parts by weight of water.
17. The method of claim 1 , wherein said drug has a solubility in water of greater than one part by weight of said drug in ten parts by weight of water.
18. The method of claim 1 , wherein said drug is a member selected from the group consisting of metformin hydrochloride, vancomycin hydrochloride, captopril, lisinopril, erythromycin lactobionate, acyclovir, ranitidine hydrochloride, baclofen, sertraline hydrochloride, levodopa, tramadol, and ticlopidine hydrochloride.
19. The method of claim 1 , wherein said drug is a member selected from the group consisting of amoxicillin, cefuroxime axetil, cefaclor, clindamycin, clarithromycin, azithromycin, ceftazidime, and ciprofloxacin.
20. The method of claim 1 , wherein said drug is a member selected from the group consisting of cyclosporine, digoxin, doxifluridine, and paclitaxel.